Medical Device Regulatory Strategy

Decision-Level Clarity | Medical Device Regulatory Strategy and FDA Advisory

Medical Devices | Any Type

In-Vitro Diagnostics (IVD)

Wellness Devices

Combination Devices

Regulatory Strategy | Pathway Assessment

Medical device regulatory strategy is shaped by both near‑term decisions and long‑term objectives. Accordingly, our work focuses on identifying viable regulatory paths and the tradeoffs associated with each.
 
  • Strategy development that considers both near- and long-term plans
  • Evaluation of regulatory pathways in light of business objectives and constraints
  • Strategic assessment of whether and when to engage the FDA through Q‑Submissions (Q‑Sub, Pre-Sub)
  • Identification of device risks and regulatory tradeoffs to support informed decision-making
  • Application of agency guidance and consideration of their current thinking, specific to the device’s technology and intended use

Pathway Planning | Agency Engagement and Submissions

Once a regulatory direction is defined, attention shifts to execution and agency interaction. In practice, this involves disciplined planning and proportionate engagement.
 
  • As part of early pathway planning, evaluation of administrative and classification routes, including 513(g) requests where appropriate
  • Regulatory authority engagement, including meeting strategy, formal correspondence, and issue resolution
  • Principled application of the FDA’s Least Burdensome Approach to support reasoned, proportionate agency requests
  • Targeted review and refinement of technical documentation, test report elements, and device labeling to support submission readiness

Additional Device-Dependent support Services

Depending on device type, development stage, and organizational needs, additional regulatory support may be appropriate.
 
  • Design control considerations before and after submission
  • Risk management development for device classification and clinical study planning, including IDE risk determination
  • Human factors and usability considerations aligned with FDA guidance and ISO/IEC 62366, as applicable
  • Advisory for software as a medical device or integral to a device, including artificial intelligence (AI)
  • Establishment registration (foreign and domestic) and product/device listing
  • Support for regulatory inspections, audits, and related agency reviews
  • Quality management system assessment, e.g. FDA Quality Management System Regulation (QMSR), Current Good Manufacturing Practices (CGMPs) and ISO 13485 Medical Device Quality Management (QMS)
  • Other regulatory advisory discussions relevant to the device and company goals 
US FDA Medical Device Regulatory Strategy

Meeting Your Stakeholder's Needs

Our advisory supports medical device companies by aligning regulatory strategy with business objectives, investor priorities, patient impact, and regulatory expectations—applied through a least‑burdensome, risk‑appropriate lens. In practice, this yields durable regulatory pathways that integrate into leadership planning and stakeholder communication.
Scroll to Top